Targeting Pathophysiologic Pathways in Cervical Cancer: Why Immunotherapy?

Program Overview

This 15-minute infographic activity uses an interactive approach augmented by a whiteboard animation and clinician videos to delineate immunotherapy rationale, mechanism of action, and safety considerations in cervical cancer.

Credit Expired

Target Audience

This activity is intended for oncology, pathology, gynecologic oncology, and OB/GYN clinicians (MD/DO/NP/PA) who treat patients with cervical cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Align the mechanism of action of immune checkpoint inhibitors with underlying cervical cancer processes

Activity Faculty

Krishnansu S. Tewari, MD, FACOG, FACS, FRSM

Professor and Division Director
Division of Gynecologic Oncology
University of California
Irvine, CA

Featured RMEI CE Activities – Earn CE Credit(s)

A Non-CME Educational Program during the 2025 AAAAI/WAO Joint Congress: Expert Panel Discussion Featuring a Patient

A Violent Graft in a Vulnerable Host: The Future of aGvHD Management: A Care Team Forum®

1.5 CE Credit(s)

Rapid Recognition and Management of T-Cell Therapy-Related Toxicities in B-Cell Lymphomas: Crucial Updates for the Emergency Department

1.0 CE Credit(s)

Privacy | Terms of Use